mantle cell lymphoma

[Bone Marrow Transplantation] The ASTCT, CIBMTR, and the EBMT, jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-, allo-hematopoietic cell transplantation, and chimeric antigen receptor T-cell therapy for patients with newly diagnosed and relapsed/refractory mantle cell lymphoma.

[Haematologica] By implementing pharmacogenomics and a cell-based drug screen, scientists found that THZ531 led to inhibition of oncogenic transcriptional programs, especially the DNA damage response pathway, MYC target genes and the mTOR-4EBP1-MCL-1 axis, contributing to dramatic lymphoma suppression in vitro.

[Blood Advances] Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase I/II study in patients with various B-cell malignancies. Zanubrutinib was well tolerated and demonstrated activity in patients with relapsed/refractory mantle cell lymphoma.

[Scientific Reports] Researchers found that acute lymphoblastic leukemia cells expressing MLL–AF4 fusion protein expressed high levels of lymphoid tissue-specific immunoproteasomes and were sensitive to pharmacologically relevant concentrations of specific immunoproteasome inhibitor ONX-0914.

[Nature Communications] The authors characterized the cellular and molecular heterogeneity within and across patients and delineate the dynamic evolution of tumor and immune cell compartments at single cell resolution in longitudinal specimens from ibrutinib-sensitive patients and non-responders.

[Acta Pharmacologica Sinica] Scientists report that a p300/CBP inhibitor, A-485, could overcome resistance to idelalisib in mantle cell lymphoma cells in vitro and in vivo.